Research Analysts Offer Predictions for STOK FY2029 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Wedbush issued their FY2029 earnings estimates for shares of Stoke Therapeutics in a note issued to investors on Tuesday, January 7th. Wedbush analyst L. Chico forecasts that the company will earn ($0.41) per share for the year. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.03) per share.

A number of other equities analysts also recently issued reports on the company. Leerink Partnrs upgraded Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. Leerink Partners started coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an "outperform" rating and a $18.00 price objective on the stock. Chardan Capital started coverage on shares of Stoke Therapeutics in a report on Friday, December 20th. They issued a "buy" rating and a $24.00 target price for the company. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $21.29.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock traded down $0.35 during trading hours on Thursday, reaching $8.96. The company's stock had a trading volume of 1,037,383 shares, compared to its average volume of 991,057. The company has a market capitalization of $474.58 million, a P/E ratio of -4.27 and a beta of 0.95. The stock's fifty day simple moving average is $11.98 and its two-hundred day simple moving average is $13.08. Stoke Therapeutics has a one year low of $4.09 and a one year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Lynx1 Capital Management LP lifted its stake in Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock worth $70,052,000 after purchasing an additional 1,488,371 shares in the last quarter. RTW Investments LP boosted its stake in Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock valued at $57,177,000 after buying an additional 427,447 shares during the period. State Street Corp grew its position in Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company's stock worth $21,248,000 after buying an additional 137,145 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock valued at $18,741,000 after acquiring an additional 1,123,500 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of Stoke Therapeutics by 550.1% during the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company's stock worth $15,686,000 after purchasing an additional 982,451 shares in the last quarter.

Insider Buying and Selling at Stoke Therapeutics

In related news, insider Barry Ticho sold 10,000 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total transaction of $120,700.00. Following the sale, the insider now directly owns 51,277 shares in the company, valued at approximately $618,913.39. This represents a 16.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $78,852.60. Following the completion of the transaction, the chief executive officer now owns 68,671 shares of the company's stock, valued at $877,615.38. This represents a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock worth $809,421 over the last ninety days. 11.30% of the stock is currently owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.